Crispr Therapeutics AG (CRSP) — Strategic Asset Allocation Index
Crispr Therapeutics AG (CRSP) has a Strategic Asset Allocation Index of 1.5% as of September 2025. Strategic assets (PP&E of $- plus long-term investments of $28.41 Million) total $28.41 Million, measured against net assets of $1.92 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Crispr Therapeutics AG Strategic Asset Allocation Index (2016–2024)
This chart shows how Crispr Therapeutics AG's Strategic Asset Allocation Index has evolved across 9 annual periods from 2016 to 2024. As of September 2025, the index stands at 1.5%, representing strategic assets of $28.41 Million against net assets of $1.92 Billion USD. Explore cash flow conversion of Crispr Therapeutics AG to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Crispr Therapeutics AG (2016–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Crispr Therapeutics AG from 2016 to 2024, covering 9 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see market value of Crispr Therapeutics AG.
| Year | SAAI | Strategic Assets (USD) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 0.0% | $0.00 | $- | $0.00 | $1.93 Billion | ▼ -0.1 pp |
| 2023 | 0.1% | $1.97 Million | $- | $1.97 Million | $1.88 Billion | ▼ -11.5 pp |
| 2022 | 11.6% | $216.76 Million | $163.63 Million | $53.13 Million | $1.88 Billion | ▲ +5.8 pp |
| 2021 | 5.7% | $137.57 Million | $137.57 Million | $0.00 | $2.40 Billion | ▲ +3.2 pp |
| 2020 | 2.5% | $42.16 Million | $42.16 Million | $- | $1.66 Billion | ▼ -5.2 pp |
| 2019 | 7.8% | $72.83 Million | $72.83 Million | $- | $939.42 Million | ▲ +3.0 pp |
| 2018 | 4.7% | $18.50 Million | $18.50 Million | $- | $392.19 Million | ▼ -5.3 pp |
| 2017 | 10.0% | $18.86 Million | $18.86 Million | $- | $187.83 Million | ▲ +1.0 pp |
| 2016 | 9.0% | $21.03 Million | $21.03 Million | $- | $232.85 Million | — |